California-based Artera, which offers an AI-enabled test aimed at personalizing therapy for prostate cancer patients, announces its launch alongside a $90 million investment.
Johnson & Johnson, TIME Ventures, Koch Disruptive Technologies, Coatue, Walden Catalyst Ventures, The Factory and Breyer Capital participated in the round alongside angel investors Amarjit Gill, Clarence So, Marc Benioff...
Singapore-headquartered Qritive has integrated its AI modules with US-based Corista's image management platform DP3.
According to a press statement, the combined solution leverages AI to screen for both prostate and colon cancers, quantify IHC markers, and detect lymph node metastasis.
It allows pathologists to prioritise and grade specific cases while improving the detection of hard-to-...
Avenda Health received FDA 510(k) clearance for AI-backed clinical decision support software that assists physicians in prostate cancer care.
iQuest, which officially received the agency green light late last month, is meant to be used alongside MRI and biopsy results. The system uses specific patient data and deep learning to build a "tailored map" showing where cancer is located in the prostate...
Consumer genetics company 23andMe scored FDA 510(k) clearance for a test to detect a hereditary marker for prostate cancer.
The risk report provides information on whether users have the G84E mutation in the HOXB13 gene, which studies have shown can increase a person’s risk of developing prostate cancer.
This FDA greenlight marks 23andMe’s third 510(k). It also has four De Novo clearances, one of...
Paige, a digital pathology diagnostics company, has received De Novo marketing authorization from the Food and Drug Administration for its artificial intelligence software that helps detect prostate cancer.
The Paige Prostate software analyzes digitized biopsy slides and identifies areas that could be cancerous for the pathologist to review further.
“The approval is a landmark achievement in the...
Social media awareness around the BRCA1 and 2 mutations' links to prostate cancer is significantly lower than public awareness around the mutations' links to breast cancer, according to a recent study published by JMIR.
Researchers found that social media posts on Twitter, Facebook and YouTube regarding the BRCA gene and genetic testing are much less prevalent than those regarding the gene's ...
The past couple of days have seen a handful of artificial intelligence algorithms for radiology imaging analysis receive 510(k) clearances from the FDA. Two of these, from Quantib and Ezra, are focused on the relatively untouched area of prostate cancer screening, while a third, from Aidoc, targets incidental pulmonary embolism.
Quantib's software delivers an in-workflow assessment of prostate...
Last month, the CDC launched a prostate cancer information program with a uniquely digital face: a "virtual human" named Nathan who speaks with men about screening and treatment.
"Talk to Someone About Prostate Cancer" takes the form of an in-browser interactive video developed by health simulation company Kognito, where Nathan introduces himself and prompts the viewer by asking how confident...
Last week New York-based, AI-powered cancer screening platform Ezra announced that it scored $4 million in a seed funding led by Accomplice, with additional funding from Founders Future, Credo Ventures, Seedcamp, Esther Dyson and various unnamed startup founders and angel investors.
This funding announcement is paired with the beta launch of its prostate cancer screening program. Right now the...
The American Cancer Society is supporting research at the the Feinstein Institute for Medical Research (the research arm of New York’s Northwell Health system), which is working on an app to guide people living with prostate cancer through the treatment decision process.
Dr. Michael Diefenbach, director of behavioral research at Northwell Health’s department of medicine and urology and a...
